Daptomycin (5 brand names, 2 dosage forms, 1 route)
Available dosage forms: POWDER, SOLUTION.
Routes of administration: INTRAVENOUS.
Brand Names
- CUBICIN
- CUBICIN RF
- DAPTOMYCIN
- DAPTOMYCIN IN 0.9% SODIUM CHLORIDE
- DAPZURA RT
Contraindications
DAPZURA RT is contraindicated in: • Patients with known hypersensitivity to daptomycin [see Warnings and Precautions (5.1)]. • Patients with known or suspected Hereditary Fructose Intolerance (HFI) [see Warnings and Precautions (5.11) ].
Adverse Reactions
The following adverse reactions are described, or described in greater detail, in other sections: •Anaphylaxis/Hypersensitivity Reactions [see Warnings and Precautions (5.1)] •Myopathy and Rhabdomyolysis [see Warnings and Precautions (5.2)] •Eosinophilic Pneumonia [see Warnings and Precautions (5.3)] •Drug Reaction with Eosinophilia and Systemic Symptoms [see Warnings and Precautions (5.4)] •Tubulointerstitial Nephritis [see Warnings and Precautions (5.5)] •Peripheral Neuropathy [see Warnings and Precautions (5.6)] •Increased International Normalized Ratio (INR)/Prolonged Prothrombin Time [see Warnings and Precautions (5.12) and Drug Interactions (7.2)]
Mechanism of Action
Daptomycin is an antibacterial drug [see Clinical Pharmacology (12.4)].
Overdosage
In the event of overdosage, supportive care is advised with maintenance of glomerular filtration. Daptomycin is cleared slowly from the body by hemodialysis (approximately 15% of the administered dose is removed over 4 hours) and by peritoneal dialysis (approximately 11% of the administered dose is removed over 48 hours). The use of high-flux dialysis membranes during 4 hours of hemodialysis may increase the percentage of dose removed compared with that removed by low-flux membranes.